• OSR Holdings entered a definitive global exclusive license agreement with BCM Europe for development and commercialization of VXM01, a Phase 3-ready oral immunotherapy targeting VEGFR-2.
• Deal terms include up to USD 815 million in milestone payments tied to clinical, regulatory, and commercial progress.
• BCM Europe pledged its full OSR Holdings equity stake, about 29.7%, as collateral for milestone obligations.
• OSR Holdings plans to acquire full VXM01 intellectual property from Vaximm under a USD 30 million asset purchase agreement.
• Agreement includes a put option allowing OSR Holdings to require BCM Europe to buy up to USD 15 million of common stock at USD 10 per share, exercisable no earlier than six months from the effective date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSR Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604290950ACCESSWRNAPR_____1162353) on April 29, 2026, and is solely responsible for the information contained therein.